Aromatase Inhibitor for Treatment of Resected Grade I, II or III Breast Cancer
This study is currently recruiting patients.
Verified by Mayo Clinic August 2006
Sponsors and Collaborators:
Mayo Clinic M.D. Anderson Cancer Center
Information provided by:Mayo ClinicClinicalTrials.gov Identifier:NCT00366054
Purpose
Study to determine if genotype determines response to Aromatase Inhibitors ie: Decrease in hormone and drug levels.
Condition Breast Cancer